Preview Mode Links will not work in preview mode

This Week in Cardiology

Mar 4, 2022

An update to CardioMEMs post, ARBs and cancer, troponins, empagliflozin, and low-value care are the topics discussed by John Mandrola, MD, in this week’s podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I – Invasive Monitoring for HF

- FDA Expands Eligibility for CardioMEMS Heart Failure System

- Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

II – ARBs and Cancer

- ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again

- Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials

- Marciniak Meta-analysis in FDA Medical Review 206316Orig1Orig2s000

III – Troponins and Cardiac Surgery

- What Troponin Level Indicates Injury After Cardiac Surgery?

- High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality

- Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease

IV – Empagliflozin in HFpEF

- FDA Okays Empagliflozin for HF Regardless of Ejection Fraction

- Empagliflozin in Heart Failure with a Preserved Ejection Fraction

- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

V – Low-Value Care

- AHA Targets 'Low-Value' Heart Care in New Scientific Statement

- Strategies to Reduce Low-Value Cardiovascular Care: A Scientific Statement From the American Heart Association

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact